OBJECTIVES: HTA in Taiwan was established in December 2007 to inform decision making on drug approvals and reimbursement prices. Drug categories were established based on the therapeutic value and the innovative nature of new drugs, and various pricing structures were adopted. Price adjustments based on demonstrative improvements in clinical efficacy and safety are also able to be applied. These adjustments can take into account clinical and pharmacoeconomic data specifically relevant to Taiwan. The aim of this study was to investigate the reimbursements of new health technologies assessed by the NIHTA with respect to drug categorisation, pricing structures and applied price adjustments. METHODS: NIHTA assessment reports from 2011 to February 2014 were reviewed, and approval and pricing decisions by the NHIA were evaluated. RESULTS: Of the 52 assessments included in this analysis, 37 were approved for use on the National Health Insurance (NHI) in Taiwan. Of these, 57% were determined as having a comparable therapeutic value to the current best competitor, 38% were deemed to show moderate improvements and 5% were considered breakthrough innovations. In most instances (73%), drugs were priced based on existing therapies. Of the approved health technologies, 9 (24%) were eligible for additional price adjustments. These were spread across multiple disease areas and reflected improved clinical and safety outcomes, dosing convenience and the availability of local clinical and economic data. The incidence of price adjustments has increased in recent years, which is particularly evident with respect to high quality pharmacoeconomic data. CONCLUSIONS: The majority of drugs approved by the NHIA offer similar clinical benefit to current competitors and are priced based on existing therapies. Alternative methods involved calculating drug prices based on international reference countries, although manufacturers seem to be increasingly seeking available price adjustments to achieve a higher price for their product.